The Muscle Spasticity drugs in development market research report provides comprehensive information on the therapeutics under development for Muscle Spasticity, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Muscle Spasticity. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights Muscle Spasticity - Drugs In Development, 2023

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Muscle Spasticity and features dormant and discontinued products.

GlobalData tracks 32 drugs in development for Muscle Spasticity by 29 companies/universities/institutes. The top development phase for Muscle Spasticity is preclinical with ten drugs in that stage. The Muscle Spasticity pipeline has 31 drugs in development by companies and one by universities/ institutes. Some of the companies in the Muscle Spasticity pipeline products market are: CytoDel, Phase V Pharmaceuticals and Huons.

The key targets in the Muscle Spasticity pipeline products market include Synaptosomal Associated Protein 25 (Synaptosomal Associated 25 kDa Protein or Super Protein or SNAP25), Cannabinoid Receptor 1 (CB1 or CANN6 or CNR1), and Cannabinoid Receptor 2 (CB2 or CX5 or CNR2).

The key mechanisms of action in the Muscle Spasticity pipeline product include Synaptosomal Associated Protein 25 (Synaptosomal Associated 25 kDa Protein or Super Protein or SNAP25) Inhibitor with ten drugs in Phase III. The Muscle Spasticity pipeline products include eight routes of administration with the top ROA being Intramuscular and five key molecule types in the Muscle Spasticity pipeline products market including Small Molecule, and Protein.

Muscle Spasticity overview

Muscle spasticity is a condition that causes muscles to contract, stiffen, or spasm involuntarily, affecting movement, speech, and gait. It is caused by damage or disruption to the nerve pathways that control muscle movement, usually due to brain or spinal cord injury, cerebral palsy, multiple sclerosis, or other diseases. Spasticity can range from mild to severe and can cause pain, deformity, fatigue, and difficulty performing daily tasks. Spasticity can be treated with physical therapy, medication, surgery, or other methods depending on the cause and severity of the condition.

For a complete picture of Muscle Spasticity’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.